×
Abbvie Inc
Strengths
4
Weakness
19
Opportunity
2
Threats
1
- Turnaround Companies: Loss to Profit QoQ
- Annual Profit Growth higher than Sector Profit Growth
- PEG lower than Industry PEG
- Top Gainers
- Promoter decreasing their shareholding
- MACD Crossover Below Signal Line
- PE higher than Industry PE
- Momentum Trap (DVM)
- Companies with High Debt
- High PE (PE > 40)
- Await Turnaround (DVM)
- Stocks with Expensive Valuations according to the Trendlyne Valuation Score
- Risky Value (DVM)
- Low durability companies
- Inefficient use of assets to generate profits - ROA declining in the last 2 years
- Poor cash generated from core business - Declining Cash Flow from Operations for last 2 years
- MACD crossed below signal line previous end of day
- Companies with Increasing Debt
- Declining Net Cash Flow : Companies not able to generate net cash
- Annual net profit declining for last 2 years
- Book Value Per Share deteriorating for last 2 years
- Sell Zone: Stocks in the sell zone based on days traded at current PE and P/BV
- Stocks Underperforming their Industry Price Change in the Quarter
- Mutual Funds Increased Shareholding in Past Month
- Institutions increasing their shareholding
- MFs decreased their shareholding last quarter
Note: Financial Information is based on numbers.
Market Capitalization
High in industry
327,650.1
PE TTM
High in industry
78.1
PEG TTM
Negative PEG TTM
-2.6
Price to Book
High in industry
230.7
Operating Profit Margin Qtr %
High in industry
29.8
Dividend yield 1yr %
Below industry Median
0.8
Oper Rev Qtr
8.4% incr over last year
13,343
Net Profit Qtr
6% decr over last year
1,286
Operating Profit Qtr
34.4% incr over last year
3,981
Operating Revenue TTM
5.5% incr over last year
57,367
Net profit TTM
30% decr over last year
4,195
Basic EPS TTM
30% decr over last year
2.4
RSI
RSI is mid-range
45.4
MFI
MFI Overbought
75.8
PAST EVENT
•
Jun 10, 2025
Board Meeting - 46th Annual Goldman Sachs Global Healthcare Conference
The latest board meeting for Abbvie Inc took place on Jun 10, 2025, for the purpose of 46th Annual Goldman Sachs Global Healthcare Conference
.
*All Financial parameters are in Million USD.
Abbvie Inc EMA & SMA
185.49
↑
0.01%
CURRENT PRICE
Bullish Moving Averages
Bearish Moving Averages
5 Day
187.8
10 Day
188.3
12 Day
188.2
20 Day
187.8
26 Day
187.7
50 Day
188.3
100 Day
188.8
200 Day
186.4
5 Day
189.1
10 Day
189.3
20 Day
187.1
30 Day
186.4
50 Day
184.8
100 Day
192.7
150 Day
186.8
200 Day
188.7
Abbvie Inc DELIVERY AND VOLUME
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
Abbvie Inc RESISTANCE AND SUPPORT
185.44
PIVOT
First Resistance
187.2
Second Resistance
188.9
Third Resistance
190.6
First Support
183.8
Second Support
182.0
Third Support
180.3
Abbvie Inc BETA
1 Month
-0.1
1 Year
-0.2
3 Months
-0.2
3 Years
-0.1
Abbvie Inc PRICE CHANGE ANALYSIS
↑
0.8%
Over 1 Month
Low
High
180.3
193.6
↓
-13.3%
Over 3 Months
Low
High
164.4
214.5
↑
5.6%
Over 6 Months
Low
High
164.4
218.7
↑
8.2%
Over 1 Year
Low
High
163.5
218.7
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|
| SUSAN E. QUAGGIN | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| JENNIFER L. DAVIS | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| MELODY B. MEYER | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| WILLIAM H.L. BURNSIDE | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| BRETT J. HART | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| ROXANNE S. AUSTIN | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| EDWARD J. RAPP | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| THOMAS C. FREYMAN | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| ROBERT J. ALPERN | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| REBECCA B. ROBERTS | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| GLENN F. TILTON | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| FREDERICK H. WADDELL | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2025 | 1,203 | Common Stock, $0.01 par value | ||
| SUSAN E. QUAGGIN | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 71 | Stock Equivalent Units | ||
| JEFFREY RYAN STEWART | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 210.54 per share. | 31 Mar 2025 | 33,132 | 210.5 | 6,975,611.00 | Common Stock, $0.01 par value |
| JEFFREY RYAN STEWART | EVP, CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 209.49 per share. | 31 Mar 2025 | 25,700 | 209.5 | 5,383,893.00 | Common Stock, $0.01 par value |
| JEFFREY RYAN STEWART | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 79.02 per share. | 31 Mar 2025 | 25,700 | 79.0 | 2,030,814.00 | Common Stock, $0.01 par value |
| JEFFREY RYAN STEWART | EVP, CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 25,700 | Option (Right to Buy) | ||
| RICHARD A. GONZALEZ | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Mar 2025 | 2,450 | Common Stock, $0.01 par value | ||
| EDWARD J. RAPP | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 155 | Stock Equivalent Units | ||
| ROBERT J. ALPERN | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 35 | Stock Equivalent Units | ||
| SCOTT REENTS | EVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 212.34 per share. | 14 Mar 2025 | 17,644 | 212.3 | 3,746,527.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Sale of securities on an exchange or to another person at price $ 210.00 per share. | 28 Feb 2025 | 18,008 | 210 | 3,781,680.00 | Common Stock, $0.01 par value |
| RICHARD A. GONZALEZ | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 73,209 | 205.0 | 15,009,309.00 | Common Stock, $0.01 par value |
| RICHARD A. GONZALEZ | Director | Sale of securities on an exchange or to another person at price $ 205.11 per share. | 28 Feb 2025 | 92,460 | 205.1 | 18,964,471.00 | Common Stock, $0.01 par value |
| RICHARD A. GONZALEZ | Director | Sale of securities on an exchange or to another person at price $ 210.53 per share. | 28 Feb 2025 | 6,168 | 210.5 | 1,298,549.00 | Common Stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 16,904 | 205.0 | 3,465,658.00 | Common stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Sale of securities on an exchange or to another person at price $ 209.80 per share. | 28 Feb 2025 | 5,677 | 209.8 | 1,191,035.00 | Common stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Sale of securities on an exchange or to another person at price $ 210.66 per share. | 28 Feb 2025 | 14,973 | 210.7 | 3,154,212.00 | Common stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Sale of securities on an exchange or to another person at price $ 211.32 per share. | 28 Feb 2025 | 600 | 211.3 | 126,792.00 | Common stock, $0.01 par value |
| AZITA SALEKI-GERHARDT | EVP, CHIEF OPERATIONS OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 17,056 | 205.0 | 3,496,821.00 | Common Stock, $0.01 par value |
| ROBERT A. MICHAEL | Director, CHIEF EXECUTIVE OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 27,186 | 205.0 | 5,573,674.00 | Common Stock, $0.01 par value |
| JEFFREY RYAN STEWART | EVP, CHIEF COMMERCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 20,226 | 205.0 | 4,146,735.00 | Common Stock, $0.01 par value |
| NICHOLAS J. DONOGHOE | EVP, CHIEF BUS/STRAT OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 11,230 | 205.0 | 2,302,375.00 | Common Stock, $0.01 par value |
| SCOTT REENTS | EVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 10,973 | 205.0 | 2,249,684.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Sale of securities on an exchange or to another person at price $ 206.62 per share. | 28 Feb 2025 | 6,811 | 206.6 | 1,407,289.00 | Common Stock, $0.01 par value |
| ROOPAL THAKKAR | EVP, R&D and CSO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 4,678 | 205.0 | 959,084.00 | Common Stock, $0.01 par value |
| KEVIN K. BUCKBEE | SVP, CONTROLLER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 3,699 | 205.0 | 758,369.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 149.62 per share. | 28 Feb 2025 | 7,315 | 149.6 | 1,094,470.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 175.28 per share. | 28 Feb 2025 | 7,775 | 175.3 | 1,362,802.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2025 | 2,918 | Option (Right to buy) | ||
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2025 | 7,775 | Option (Right to buy) | ||
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Sale or transfer of securities back to the company at price $ 0.00 per share. | 28 Feb 2025 | 7,315 | Option (Right to buy) | ||
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Sale of securities on an exchange or to another person at price $ 207.19 per share. | 28 Feb 2025 | 363 | 207.2 | 75,210.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Payment of exercise price or tax liability using portion of securities received from the company at price $ 205.02 per share. | 28 Feb 2025 | 7,870 | 205.0 | 1,613,507.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Exercise or conversion of derivative security received from the company (such as an option) at price $ 144.54 per share. | 28 Feb 2025 | 2,918 | 144.5 | 421,768.00 | Common Stock, $0.01 par value |
| PERRY C. SIATIS | EVP, GC AND SECRETARY | Sale of securities on an exchange or to another person at price $ 205.38 per share. | 28 Feb 2025 | 2,718 | 205.4 | 558,223.00 | Common Stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Sale of securities on an exchange or to another person at price $ 201.97 per share. | 26 Feb 2025 | 4,308 | 202.0 | 870,087.00 | Common stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 114.36 per share. | 26 Feb 2025 | 22,210 | 114.4 | 2,539,936.00 | Common stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Sale of securities on an exchange or to another person at price $ 202.93 per share. | 26 Feb 2025 | 4,781 | 202.9 | 970,208.00 | Common stock, $0.01 par value |
| TIMOTHY J. RICHMOND | EVP, CHIEF HR OFFICER | Sale of securities on an exchange or to another person at price $ 202.92 per share. | 26 Feb 2025 | 13,073 | 202.9 | 2,652,773.00 | Common stock, $0.01 par value |
Security Type:
Share/ Warrants / Convertible Debentures
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Data as reported to USA Exchanges
| Ex-Date | Dividend Amount | Record Date | Instrument Type |
|---|---|---|---|
| 15 Apr, 2025 | 1.64 | 15 Apr, 2025 | Equity Share |
| 15 Jan, 2025 | 1.64 | 15 Jan, 2025 | Equity Share |
| 15 Oct, 2024 | 1.55 | 15 Oct, 2024 | Equity Share |
| 15 Jul, 2024 | 1.55 | 15 Jul, 2024 | Equity Share |
| 12 Apr, 2024 | 1.55 | 15 Apr, 2024 | Equity Share |
| 12 Jan, 2024 | 1.55 | 16 Jan, 2024 | Equity Share |
| 12 Oct, 2023 | 1.48 | 13 Oct, 2023 | Equity Share |
| 13 Jul, 2023 | 1.48 | 14 Jul, 2023 | Equity Share |
| 13 Apr, 2023 | 1.48 | 14 Apr, 2023 | Equity Share |
| 12 Jan, 2023 | 1.48 | 13 Jan, 2023 | Equity Share |
| 13 Oct, 2022 | 1.41 | 14 Oct, 2022 | Equity Share |
| 14 Jul, 2022 | 1.41 | 15 Jul, 2022 | Equity Share |
| 13 Apr, 2022 | 1.41 | 15 Apr, 2022 | Equity Share |
| 13 Jan, 2022 | 1.41 | 14 Jan, 2022 | Equity Share |
| 14 Oct, 2021 | 1.30 | 15 Oct, 2021 | Equity Share |
| 14 Jul, 2021 | 1.30 | 15 Jul, 2021 | Equity Share |
| 14 Apr, 2021 | 1.30 | 15 Apr, 2021 | Equity Share |
| 14 Jan, 2021 | 1.30 | 15 Jan, 2021 | Equity Share |
| 14 Oct, 2020 | 1.18 | 15 Oct, 2020 | Equity Share |
| 14 Jul, 2020 | 1.18 | 15 Jul, 2020 | Equity Share |
| 14 Apr, 2020 | 1.18 | 15 Apr, 2020 | Equity Share |
| 14 Jan, 2020 | 1.18 | 15 Jan, 2020 | Equity Share |
| 11 Oct, 2019 | 1.07 | 15 Oct, 2019 | Equity Share |
| 12 Jul, 2019 | 1.07 | 15 Jul, 2019 | Equity Share |
| 12 Apr, 2019 | 1.07 | 15 Apr, 2019 | Equity Share |
| 14 Jan, 2019 | 1.07 | 15 Jan, 2019 | Equity Share |
| 12 Oct, 2018 | 0.96 | 15 Oct, 2018 | Equity Share |
| 12 Jul, 2018 | 0.96 | 13 Jul, 2018 | Equity Share |
| 12 Apr, 2018 | 0.96 | 13 Apr, 2018 | Equity Share |
| 11 Jan, 2018 | 0.71 | 12 Jan, 2018 | Equity Share |
| 12 Oct, 2017 | 0.64 | 13 Oct, 2017 | Equity Share |
| 12 Jul, 2017 | 0.64 | 14 Jul, 2017 | Equity Share |
| 11 Apr, 2017 | 0.64 | 13 Apr, 2017 | Equity Share |
| 11 Jan, 2017 | 0.64 | 13 Jan, 2017 | Equity Share |
| 12 Oct, 2016 | 0.57 | 14 Oct, 2016 | Equity Share |
| 13 Jul, 2016 | 0.57 | 15 Jul, 2016 | Equity Share |
| 13 Apr, 2016 | 0.57 | 15 Apr, 2016 | Equity Share |
| 13 Jan, 2016 | 0.57 | 15 Jan, 2016 | Equity Share |
| 13 Oct, 2015 | 0.51 | 15 Oct, 2015 | Equity Share |
| 13 Jul, 2015 | 0.51 | 15 Jul, 2015 | Equity Share |
| 13 Apr, 2015 | 0.51 | 15 Apr, 2015 | Equity Share |
| 13 Jan, 2015 | 0.49 | 15 Jan, 2015 | Equity Share |
| 10 Oct, 2014 | 0.42 | 15 Oct, 2014 | Equity Share |
| 11 Jul, 2014 | 0.42 | 15 Jul, 2014 | Equity Share |
| 11 Apr, 2014 | 0.42 | 15 Apr, 2014 | Equity Share |
| 13 Jan, 2014 | 0.40 | 15 Jan, 2014 | Equity Share |
| 10 Oct, 2013 | 0.40 | 15 Oct, 2013 | Equity Share |
| 11 Jul, 2013 | 0.40 | 15 Jul, 2013 | Equity Share |
| 11 Apr, 2013 | 0.40 | 15 Apr, 2013 | Equity Share |
| 11 Jan, 2013 | 0.40 | 15 Jan, 2013 | Equity Share |
| Ex-Date | Purpose | Notes |
|---|---|---|
| 08 May, 2026 | AbbVie Inc Annual General Meeting for 2026 | None |
| 24 Apr, 2026 | AbbVie Inc First Quarter Earnings Results for 2026 | None |
| 24 Apr, 2026 | AbbVie Inc First Quarter Earnings Conference Call for 2026 | None |
| 13 Feb, 2026 | AbbVie Inc Annual Report for 2025 | None |
| 30 Jan, 2026 | AbbVie Inc Fourth Quarter Earnings Conference Call for 2025 | None |
| 30 Jan, 2026 | AbbVie Inc Fourth Quarter Earnings Results for 2025 | None |
| 30 Oct, 2025 | AbbVie Inc Third Quarter Earnings Conference Call for 2025 | None |
| 30 Oct, 2025 | AbbVie Inc Third Quarter Earnings Results for 2025 | None |
| 25 Jul, 2025 | AbbVie Inc Second Quarter Earnings Results for 2025 | None |
| 25 Jul, 2025 | AbbVie Inc Second Quarter Earnings Conference Call for 2025 | None |